The future of early cancer detection is now
A groundbreaking early detection
platform to improve patient lives
A groundbreaking early detection
platform to improve patient lives
A groundbreaking early detection
platform to improve patient lives
Our revolutionary tumor marker ganglioside platform is paving the way for life-saving early cancer detection
A novel blood test harnessing the power of tumor marker gangliosides to detect early-stage ovarian cancer
AOA Dx is pioneering the field of glycolipids through the utilization of tumor marker gangliosides, the next class of biomarkers in early cancer detection. AOA Dx is developing the first and only technology utilizing these markers with data science, providing remarkable insights into early cancer detection.
Devoted to innovation and dedicated to saving lives, AOA Dx is a team of experts and entrepreneurs that is committed to bringing impactful and cost-effective medical technologies from research and development into the hands of providers and patients.
Do you want to be a part of innovating the next class of biomarkers in early cancer detection? We would love to hear from you and work together on creating a more innovative, efficient, and patient-oriented future.
More than 90% of new discoveries in medical innovation stay in research within an academic setting and are never commercialized and widely adopted to help patients.
AOA Dx wants to ensure that patients have access to the most innovative early detection platform in their fight against cancer.
